Sanofi CEO Paul Hudson believes 2023 will be one of the “most important years in the company’s history.” The French pharma giant is riding on the success of Dupixent, with positive data for COPD patients, while bidding goodbye to its last major patent expiry for several more years.
In an exclusive interview with Endpoints News, Hudson talked about the company’s pipeline, whether it was involved in bidding for Seagen, how antitrust actions in the US will affect future dealmaking, Congress’ insulin hearings, GLP-1 drugs, and more. (For our full story on the Dupixent data, click here.)
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 169,500+ biopharma pros reading Endpoints daily — and it’s free.
